November 05, 2026
This month has been marked by progress in both the regulatory and investment sides of rejuvenation biotechnology. For years, the field has faced two major challenges: scientific advances outpacing the regulatory systems meant to evaluate them, and a capital environment that has often struggled to distinguish serious translational work from noise and hype. Fortunately, recent...
October 02, 2026
At a panel in Boston, senior officials announced plans to include aging in the agency’s regulatory science agenda and discussed how therapies could move toward approval. Longevity has a partner The 2026 edition of the Aging Research and Drug Discovery Meeting (ARDD) kicked off yesterday. This is one of the biggest and longest-running longevity conferences,...
July 28, 2026
Montana’s first experimental treatment review board has brought three longevity heavyweights into the state’s effort to expand access to experimental therapies. How much regulation is too much? Many people in the longevity field will tell you that regulation is holding it back. Sensible oversight of novel therapies is essential, but an overly cautious interpretation of...